The patient's attorney alleged a deficiency against the device.Per additional information received, the patient has experienced pain, urinary problems, bowel problems, recurrence, dyspareunia (painful sexual intercourse), vaginal scarring, wound abscess, nausea, suprapubic wound hematoma, suprapubic tenderness and pressure, right groin pain, urinary incontinence, pelvic pain, urinary retention, urinary urgency, overactive bladder dysfunction, urethral obstruction, bleeding, chest pain, retractable urge urinary incontinence, nocturia, vaginal vault prolapse, cystocele, rectocele, enterocele and urinary frequency.
|
The sample was not returned.The lot number is unknown; therefore, the device history record could not be reviewed.The instructions for use which accompanies all devices currently addresses potential risks associated with surgically implanted materials.The instructions for use states in the potential complications: complications associated with the proper implantation of the pelvilace biourethral support system may include, but are not limited to: postoperative hematoma.Temporary urinary retention, bladder outlet obstruction, and voiding difficulties associated with over-correction/too much tension placed on the implant.Perforations or lacerations of vessels, nerves, bladder or bowel, which may occur during needle passage.(b)(4).The total number of events for product classification code pag is 3.Qty 2- pelvilace biourethral support system 2 needle introducers, 1 disposable handle, 4 tissue connectors, 1.5cm x 50cm porcine accellular collagen matrix sling; qty 1- pelvilace to biourethral support system needle and implant hook needle 50cm.
|